Type: drug
Status: Active — SYNCHRONIZE Program
Developer: Boehringer Ingelheim / Zealand Pharma
Survodutide targets both GLP-1 and glucagon receptors, addressing T2D, obesity, and metabolic-associated steatohepatitis (MASH) simultaneously. Phase 2b data showed MASH resolution in 83% and significant fibrosis improvement at 48 weeks. HbA1c reduced by -1.5%, body weight by -14.9%. Phase 3 SYNCHRONIZE program includes dedicated T2D and MASH arms.
Dual agonism of GLP-1 receptor (insulin secretion, appetite suppression) and glucagon receptor (hepatic lipid oxidation, energy expenditure). The glucagon component specifically drives liver fat reduction, making it uniquely effective for MASH in diabetic patients.
Year: 2025-2026